Skip to content
Triangle logo TriangleGet started
← Full study record

NCT05986682 · OUTCOME

Healthcare Resource Utilization (HCRU)

Real-World Analysis of Belantamab Mafodotin Care Patterns in Patients With Relapsed and/or Refractory Multiple Myeloma · Source last updated 2025-02-03

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.

What was measured

To the extent that they are available, HCRU \[i.e., radiation therapy, transfusions (red blood cells or platelets), inpatient admissions, treatment-related outpatient visits, emergency department visits, palliative care outpatient visits\] that occurred during BLENREP treatment will be summarized by the percentage and frequency distribution of patients with any occurrence of the respective outcome.

Groups in this outcome

Multiple Myeloma/Blenrep Participants

Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Multiple Myeloma/Blenrep Participants30

Reported measurements

Received Radiation Therapy
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants3Not reportedNot reportedNot reportedNot reported
Transfusions
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants7Not reportedNot reportedNot reportedNot reported
Inpatient Admissions
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants10Not reportedNot reportedNot reportedNot reported
Treatment-Related Outpatient Visits
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants20Not reportedNot reportedNot reportedNot reported
Emergency Department Visits
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants11Not reportedNot reportedNot reportedNot reported
Palliative Care Outpatient Visit
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Multiple Myeloma/Blenrep Participants10Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        3
    title
    Received Radiation Therapy
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        7
    title
    Transfusions
  3. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Inpatient Admissions
  4. categories
    1. measurements
      1. group Id
        OG000
        value
        20
    title
    Treatment-Related Outpatient Visits
  5. categories
    1. measurements
      1. group Id
        OG000
        value
        11
    title
    Emergency Department Visits
  6. categories
    1. measurements
      1. group Id
        OG000
        value
        10
    title
    Palliative Care Outpatient Visit
denoms
  1. counts
    1. group Id
      OG000
      value
      30
    units
    Participants
description
To the extent that they are available, HCRU \[i.e., radiation therapy, transfusions (red blood cells or platelets), inpatient admissions, treatment-related outpatient visits, emergency department visits, palliative care outpatient visits\] that occurred during BLENREP treatment will be summarized by the percentage and frequency distribution of patients with any occurrence of the respective outcome.
groups
  1. description
    Participants with relapsed and/or refractory multiple myeloma who were treated with Belantamab Mafodotin - blmf (BLENREP) in the DCI Oncology outpatient clinics between August 5, 2020 and November 7, 2023
    id
    OG000
    title
    Multiple Myeloma/Blenrep Participants
param Type
COUNT_OF_PARTICIPANTS
reporting Status
POSTED
time Frame
Between baseline and earliest of end of BLENREP treatment, death, lost to contact or end of study timeframe, up to 40 months.
title
Healthcare Resource Utilization (HCRU)
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice